Arexvy® (respiratory syncytial virus vaccine) – Expanded indication
June 7, 2024 - GSK announced the FDA approval of Arexvy (respiratory syncytial virus vaccine), for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
Top